Fundies.
English

Insider transactions

EDGAR

NovoCure Limited

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-15.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
28 transactions, 239,243.00 shares
Sum of shares × price per share: 3,395,084.207

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 79

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-09 Filed 2026-11-12Paravasthu Mukund Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)3,079.0012.862
39,602.098

Derived: shares × price per share. Exact value 39602.09800.

69,753.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $12.61 USD to $13.11 USD; the price reported above reflects the weighted average sale price.
Open filing 0002039078-26-000007 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Brackmann Christoph Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)7,343.0012.862
94,445.666

Derived: shares × price per share. Exact value 94445.66600.

175,499.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $12.61 USD to $13.11 USD; the price reported above reflects the weighted average sale price.
Open filing 0002048634-26-000003 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-04Puri Michal Nath Officer: Chief Human Resources Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)660.0013.2391
8,737.806

Derived: shares × price per share. Exact value 8737.806000.

202,567.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $13.08 USD to $13.36 USD; the price reported above reflects the weighted average sale price.
Open filing 0001997032-26-000009 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-01Ben Arye Barak Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)1,299.0011.15
14,483.85

Derived: shares × price per share. Exact value 14483.8500.

243,752.00Direct (D) No
F1, F2
  • F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (ESPP), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
  • F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Open filing 0001917165-26-000006 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-01Leonard Frank X Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)1,905.0011.15
21,240.75

Derived: shares × price per share. Exact value 21240.7500.

461,425.00Direct (D) No
F1, F2
  • F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (ESPP), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
  • F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Open filing 0001822879-26-000006 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-01Danziger Asaf Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)268.0011.15
2,988.2

Derived: shares × price per share. Exact value 2988.2000.

416,742.00Direct (D) No
F1, F2
  • F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (ESPP), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
  • F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Open filing 0001654435-26-000003 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-01Puri Michal Nath Officer: Chief Human Resources Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)1,905.0011.15
21,240.75

Derived: shares × price per share. Exact value 21240.7500.

203,227.00Direct (D) No
F1, F2
  • F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (ESPP), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
  • F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Open filing 0001997032-26-000006 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Leonard Frank X Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)34,273.0017.9335
614,634.8455

Derived: shares × price per share. Exact value 614634.845500.

459,520.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $17.665 USD to $18.37 USD; the price reported above reflects the weighted average sale price.
Open filing 0001822879-26-000004 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Scannell Timothy J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

25,898.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001451533-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Scannell Timothy J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001451533-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05VERNON W ANTHONY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

209,267.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001369091-26-000005 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05VERNON W ANTHONY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001369091-26-000005 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Stafford Kristin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

22,934.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001970438-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Stafford Kristin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001970438-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05LEUNG GABRIEL Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

101,109.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001236183-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05LEUNG GABRIEL Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001236183-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Hung David Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

32,075.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001310880-26-000006 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Hung David Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001310880-26-000006 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Ocean Allyson J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

22,934.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001967326-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Ocean Allyson J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001967326-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Madden Martin J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

30,284.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001696864-26-000001 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05Madden Martin J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001696864-26-000001 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05HILLEMAN JERYL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)11,610.000.00
0

Derived: shares × price per share. Exact value 0.0000.

25,471.00Direct (D) No
F1
  • F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001216628-26-000002 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-05HILLEMAN JERYL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (16,999.00) — exercise price 16.15		Acquired (A)16,999.000.00
0

Derived: shares × price per share. Exact value 0.0000.

16,999.00Direct (D) No
F2
  • F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Open filing 0001216628-26-000002 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-03HILLEMAN JERYL L Director
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)2,945.0015.7707
46,444.7115

Derived: shares × price per share. Exact value 46444.711500.

13,861.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.
Open filing 0001216628-26-000001 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-03VERNON W ANTHONY Director
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)2,945.0015.7707
46,444.7115

Derived: shares × price per share. Exact value 46444.711500.

197,657.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.
Open filing 0001369091-26-000004 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-03Hung David Director
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)2,945.0015.7707
46,444.7115

Derived: shares × price per share. Exact value 46444.711500.

20,465.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.
Open filing 0001310880-26-000005 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-03Ocean Allyson J Director
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)2,945.0015.7707
46,444.7115

Derived: shares × price per share. Exact value 46444.711500.

11,324.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.
Open filing 0001967326-26-000001 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-03LEUNG GABRIEL Director
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)2,945.0015.7707
46,444.7115

Derived: shares × price per share. Exact value 46444.711500.

89,499.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.
Open filing 0001236183-26-000001 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-03Stafford Kristin Director
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)2,945.0015.7707
46,444.7115

Derived: shares × price per share. Exact value 46444.711500.

11,324.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.
Open filing 0001970438-26-000001 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-03Scannell Timothy J Director
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)2,945.0015.7707
46,444.7115

Derived: shares × price per share. Exact value 46444.711500.

14,288.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.
Open filing 0001451533-26-000001 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28VERNON W ANTHONY Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares		Acquired (A)21,500.0011.39
244,885

Derived: shares × price per share. Exact value 244885.0000.

200,602.00Direct (D) No— Open filing 0001369091-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-28VERNON W ANTHONY Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (21,500.00) — exercise price 11.39		Disposed (D)21,500.000.00
0

Derived: shares × price per share. Exact value 0.0000.

0.00Direct (D) No— Open filing 0001369091-26-000002 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05Paravasthu Mukund Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)43,246.0013.774
595,670.404

Derived: shares × price per share. Exact value 595670.40400.

72,832.00Direct (D) No
F4
  • F4 This transaction was executed in multiple trades at prices ranging from $13.74 USD to $14.07 USD; the price reported above reflects the weighted average sale price.
Open filing 0002039078-26-000005 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Weinberg Uri Officer: Chf Medical and Innovation Ofr
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)6,412.0013.3054
85,314.2248

Derived: shares × price per share. Exact value 85314.224800.

267,190.00Direct (D) No
F2, F3
  • F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F3 This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Open filing 0001811030-26-000003 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Paravasthu Mukund Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)5,377.0013.3054
71,543.1358

Derived: shares × price per share. Exact value 71543.135800.

116,078.00Direct (D) No
F2, F3
  • F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F3 This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Open filing 0002039078-26-000005 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Puri Michal Nath Officer: Chief Human Resources Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)1,100.0013.3054
14,635.94

Derived: shares × price per share. Exact value 14635.940000.

201,322.00Direct (D) No
F2, F3
  • F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F3 This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Open filing 0001997032-26-000004 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Cordova Ashley Officer: Former Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Ordinary Shares		Disposed (D)17,638.0013.30
234,585.4

Derived: shares × price per share. Exact value 234585.4000.

422,570.00Direct (D) No
F1
  • F1 Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).
Open filing 0001822014-26-000003 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Leupin Nicolas Officer: Former Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)1,100.0013.3054
14,635.94

Derived: shares × price per share. Exact value 14635.940000.

102,979.00Direct (D) No
F1, F2
  • F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Open filing 0002007766-26-000003 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Brackmann Christoph Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)6,412.0013.3054
85,314.2248

Derived: shares × price per share. Exact value 85314.224800.

182,842.00Direct (D) No
F2, F3
  • F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F3 This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Open filing 0002048634-26-000001 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Leonard Frank X Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares		Disposed (D)5,607.0013.3054
74,603.3778

Derived: shares × price per share. Exact value 74603.377800.

493,793.00Direct (D) No
F2, F3
  • F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.
  • F3 This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Open filing 0001822879-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Weinberg Uri Officer: Chf Medical and Innovation Ofr
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)50,125.000.00
0

Derived: shares × price per share. Exact value 0.0000.

273,602.00Direct (D) No
F1
  • F1 Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
Open filing 0001811030-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Weinberg Uri Officer: Chf Medical and Innovation Ofr
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (73,340.00) — exercise price 13.30		Acquired (A)73,340.000.00
0

Derived: shares × price per share. Exact value 0.0000.

73,340.00Direct (D) No
F4
  • F4 Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Open filing 0001811030-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Paravasthu Mukund Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)45,112.000.00
0

Derived: shares × price per share. Exact value 0.0000.

121,455.00Direct (D) No
F1
  • F1 Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
Open filing 0002039078-26-000005 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Paravasthu Mukund Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (7,518.00) — exercise price 13.30		Acquired (A)7,518.000.00
0

Derived: shares × price per share. Exact value 0.0000.

7,518.00Direct (D) No
F5
  • F5 Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Open filing 0002039078-26-000005 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Paravasthu Mukund Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (58,488.00) — exercise price 13.30		Acquired (A)58,488.000.00
0

Derived: shares × price per share. Exact value 0.0000.

66,006.00Direct (D) No
F5
  • F5 Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Open filing 0002039078-26-000005 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Puri Michal Nath Officer: Chief Human Resources Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)40,100.000.00
0

Derived: shares × price per share. Exact value 0.0000.

202,422.00Direct (D) No
F1
  • F1 Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
Open filing 0001997032-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Puri Michal Nath Officer: Chief Human Resources Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (58,672.00) — exercise price 13.30		Acquired (A)58,672.000.00
0

Derived: shares × price per share. Exact value 0.0000.

58,672.00Direct (D) No
F4
  • F4 Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Open filing 0001997032-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Ben Arye Barak Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Ordinary Shares		Acquired (A)50,125.000.00
0

Derived: shares × price per share. Exact value 0.0000.

242,453.00Direct (D) No
F1
  • F1 Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
Open filing 0001917165-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Ben Arye Barak Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Ordinary Shares (73,340.00) — exercise price 13.30		Acquired (A)73,340.000.00
0

Derived: shares × price per share. Exact value 0.0000.

73,340.00Direct (D) No
F2
  • F2 Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Open filing 0001917165-26-000004 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–50 of 191

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
FMR LLC Partly reported under another manager17,375,855 SH277,144,893 dollarsHigher by 2,777 Prior quarter: 17,373,078Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
BlackRock, Inc. Partly reported under another manager11,863,861 SH189,228,584 dollarsLower by 1,549,838 Prior quarter: 13,413,699Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 6,493,767 SH103,575,584 dollarsHigher by 221,277 Prior quarter: 6,272,490Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 4,923,982 SH78,537,513 dollarsHigher by 20,349 Prior quarter: 4,903,633Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager4,697,120 SH74,919,087 dollarsHigher by 174,731 Prior quarter: 4,522,389Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Quantinno Capital Management LP 4,223,461 SH67,364,203 dollarsHigher by 2,000,006 Prior quarter: 2,223,455Open filing 0001759654-26-000011 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager2,927,064 SH46,686,671 dollarsHigher by 60,518 Prior quarter: 2,866,546Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager2,807,264 SH44,784,470 dollarsHigher by 8,913 Prior quarter: 2,798,351Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager2,117,711 SH33,777,490 dollarsHigher by 165,800 Prior quarter: 1,951,911Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
MACKENZIE FINANCIAL CORP 1,176,709 SH18,768,509 dollarsHigher by 1,128,237 Prior quarter: 48,472Open filing 0001062993-26-005652 Filed 2026-11-02 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager1,083,276 SH17,278,561 dollarsLower by 8,670 Prior quarter: 1,091,946Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Nuveen, LLC Partly reported under another manager1,030,910 SH16,443,015 dollarsLower by 201,177 Prior quarter: 1,232,087Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
C WorldWide Group Holding A/S Partly reported under another manager971,784 SH15,500 dollarsUnchanged Prior quarter: 971,784Open filing 0001625244-26-000010 Filed 2026-11-04 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager967,478 SH15,563,643 dollarsLower by 703,604 Prior quarter: 1,671,082Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager961,739 SH15,339,737 dollarsHigher by 39,730 Prior quarter: 922,009Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Qube Research Technologies Ltd 920,744 SH14,685,867 dollarsHigher by 314,870 Prior quarter: 605,874Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 760,846 SH12,135,494 dollarsHigher by 8,315 Prior quarter: 752,531Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 737,156 SH11,757,638 dollarsHigher by 75,876 Prior quarter: 661,280Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
PANAGORA ASSET MANAGEMENT INC 656,597 SH10,472,722 dollarsHigher by 115,910 Prior quarter: 540,687Open filing 0000883677-26-000011 Filed 2026-11-12 Dispute this row
Empowered Funds, LLC Partly reported under another manager621,157 SH9,907,454 dollarsLower by 533,274 Prior quarter: 1,154,431Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager526,906 SH8,392 dollarsHigher by 265,760 Prior quarter: 261,146Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager442,211 SH6,460,703 dollarsHigher by 7,851 Prior quarter: 434,360Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
ESSEX INVESTMENT MANAGEMENT CO LLC Partly reported under another manager424,133 SH6,764,921 dollarsLower by 15,515 Prior quarter: 439,648Open filing 0000201772-26-000007 Filed 2026-10-19 Dispute this row
CITIGROUP INC Partly reported under another manager420,188 SH6,701,999 dollarsHigher by 4,671 Prior quarter: 415,517Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 400,000 SH6,380,000 dollarsLower by 985,600 Prior quarter: 1,385,600Open filing 0001535845-26-000011 Filed 2026-11-13 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager355,982 SH5,677,913 dollarsHigher by 197,809 Prior quarter: 158,173Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
Jump Financial, LLC Partly reported under another manager343,870 SH5,484,727 dollarsHigher by 32,521 Prior quarter: 311,349Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
IEQ CAPITAL, LLC 341,782 SH5,451,423 dollarsHigher by 66,821 Prior quarter: 274,961Open filing 0001779789-26-000005 Filed 2026-11-10 Dispute this row
FIRST TRUST ADVISORS LP 335,392 SH5,349,502 dollarsHigher by 208,796 Prior quarter: 126,596Open filing 0001445546-26-008622 Filed 2026-11-12 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager303,538 SH4,841,437 dollarsLower by 1,978 Prior quarter: 305,516Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
JANE STREET GROUP, LLC Option: Call Partly reported under another manager298,900 SH4,767,455 dollarsHigher by 77,300 Prior quarter: 221,600Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
BARCLAYS PLC Partly reported under another manager280,766 SH4,478,219 dollarsHigher by 37,630 Prior quarter: 243,136Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Partly reported under another manager261,997 SH4,178,852 dollarsLower by 371 Prior quarter: 262,368Open filing 0001520354-26-000046 Filed 2026-11-13 Dispute this row
BURNEY CO/ Partly reported under another manager214,623 SH3,423,237 dollarsHigher by 89,470 Prior quarter: 125,153Open filing 0000940445-26-000005 Filed 2026-10-15 Dispute this row
Swiss National Bank 210,800 SH3,362,260 dollarsHigher by 5,300 Prior quarter: 205,500Open filing 0001582202-26-000008 Filed 2026-11-12 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager196,874 SH3,140,141 dollarsHigher by 14,358 Prior quarter: 182,516Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
Invesco Ltd. Partly reported under another manager193,566 SH3,087,377 dollarsLower by 19,806 Prior quarter: 213,372Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
Arax Advisory Partners Partly reported under another manager177,275 SH2,827,537 dollarsHigher by 150,585 Prior quarter: 26,690Open filing 0001586767-26-000009 Filed 2026-11-12 Dispute this row
CAPITAL FUND MANAGEMENT S.A. Partly reported under another manager173,462 SH2,766,718 dollarsLower by 33,820 Prior quarter: 207,282Open filing 0001323645-26-000013 Filed 2026-11-13 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager170,655 SH2,721,947 dollarsLower by 7,632 Prior quarter: 178,287Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
Focus Partners Wealth 155,180 SH2,475,122 dollarsHigher by 82,003 Prior quarter: 73,177Open filing 0001542153-26-000021 Filed 2026-11-12 Dispute this row
LOS ANGELES CAPITAL MANAGEMENT LLC 154,027 SH2,456,731 dollarsHigher by 76,021 Prior quarter: 78,006Open filing 0001177206-26-000010 Filed 2026-11-12 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager149,337 SH2,381,925 dollarsLower by 199 Prior quarter: 149,536Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager145,377 SH2,318,763 dollarsLower by 147,261 Prior quarter: 292,638Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Hillsdale Investment Management Inc. 141,900 SH2,263,305 dollarsUnchanged Prior quarter: 141,900Open filing 0001193125-26-457091 Filed 2026-11-12 Dispute this row
GROUP ONE TRADING LLC Option: Call 141,600 SH2,258,520 dollarsHigher by 13,700 Prior quarter: 127,900Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager136,366 SH2,175,038 dollarsHigher by 63,597 Prior quarter: 72,769Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
RHUMBLINE ADVISERS 135,860 SH2,166,956 dollarsHigher by 70 Prior quarter: 135,790Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
Numerai GP LLC 132,406 SH2,111,876 dollarsHigher by 55,505 Prior quarter: 76,901Open filing 0001214659-26-014140 Filed 2026-11-13 Dispute this row
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 119,644 SH1,432,552 dollarsHigher by 57,877 Prior quarter: 61,767Open filing 0001214659-26-012804 Filed 2026-10-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Soleus Capital Management, L.P. 9,913,401 SH
  • WELLS FARGO COMPANY/MN 2,528,093 SH
  • Palo Alto Investors LP 1,280,439 SH
  • JACOBS LEVY EQUITY MANAGEMENT, INC 1,164,072 SH
  • AQR CAPITAL MANAGEMENT LLC 1,102,131 SH
  • D. E. Shaw Co., Inc. 1,022,480 SH
  • NORTHERN TRUST CORP 973,202 SH
  • GOLDMAN SACHS GROUP INC 963,917 SH
  • BAILLIE GIFFORD CO 952,074 SH
  • SILVERCREST ASSET MANAGEMENT GROUP LLC 928,740 SH
  • Sixth Street Partners Management Company, L.P. 923,670 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 923,670 SH
  • ALGERT GLOBAL LLC 856,322 SH
  • Point72 Asset Management, L.P. 803,120 SH
  • BANK OF AMERICA CORP /DE/ 762,724 SH
  • Balyasny Asset Management L.P. 479,999 SH
  • SCHRODER INVESTMENT MANAGEMENT GROUP 415,340 SH
  • HRT FINANCIAL LP 392,319 SH
  • Legal General Group Plc 325,809 SH
  • Susquehanna Portfolio Strategies, LLC 288,772 SH
  • MILLENNIUM MANAGEMENT LLC 278,068 SH
  • TUDOR INVESTMENT CORP ET AL 269,027 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 198,800 SH
  • CITADEL ADVISORS LLC 197,600 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 174,244 SH
  • Trexquant Investment LP 166,278 SH
  • CITADEL ADVISORS LLC 157,235 SH
  • Allianz Asset Management GmbH 148,411 SH
  • PRICE T ROWE ASSOCIATES INC /MD/ 143,949 SH
  • ALLIANCEBERNSTEIN L.P. 128,330 SH
  • TRANSCEND CAPITAL ADVISORS, LLC 117,221 SH
  • Summit Trail Advisors, LLC 98,814 SH
  • DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 98,786 SH
  • MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 93,815 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 89,800 SH
  • WELLS FARGO COMPANY/MN 85,000 SH
  • JANE STREET GROUP, LLC 81,450 SH
  • DARK FOREST CAPITAL MANAGEMENT LP 79,908 SH
  • Rhenman Partners Asset Management AB 70,000 SH
  • Engineers Gate Manager LP 69,390 SH
  • MERCER GLOBAL ADVISORS INC /ADV 68,295 SH
  • Counterpoint Mutual Funds LLC 66,849 SH
  • MetLife Investment Management, LLC 62,417 SH
  • Corient Private Wealth LP 61,650 SH
  • Man Group plc 52,718 SH
  • Jupiter Topco LLC 45,000 SH
  • Aquatic Capital Management LLC 39,262 SH
  • Coppell Advisory Solutions LLC 38,953 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 38,693 SH
  • SG Americas Securities, LLC 33,229 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Soleus Capital Master Fund, L.P. Ordinary Shares, no par value per share8.19,425,776.0009/30/2026 Filed 2026-11-09SCHEDULE 13G/AAmendment 5Open filing 0001213900-26-117546 Dispute this row
Soleus Capital, LLC Ordinary Shares, no par value per share8.19,425,776.0009/30/2026 Filed 2026-11-09SCHEDULE 13G/AAmendment 5Open filing 0001213900-26-117546 Dispute this row
Soleus Capital Group, LLC Ordinary Shares, no par value per share8.19,425,776.0009/30/2026 Filed 2026-11-09SCHEDULE 13G/AAmendment 5Open filing 0001213900-26-117546 Dispute this row
Soleus Capital Management, L.P. Ordinary Shares, no par value per share8.19,425,776.0009/30/2026 Filed 2026-11-09SCHEDULE 13G/AAmendment 5Open filing 0001213900-26-117546 Dispute this row
Soleus GP, LLC Ordinary Shares, no par value per share8.19,425,776.0009/30/2026 Filed 2026-11-09SCHEDULE 13G/AAmendment 5Open filing 0001213900-26-117546 Dispute this row
Levy Guy Ordinary Shares, no par value per share8.19,425,776.0009/30/2026 Filed 2026-11-09SCHEDULE 13G/AAmendment 5Open filing 0001213900-26-117546 Dispute this row
Soleus Capital Master Fund, L.P. Ordinary Shares, no par value per share9.110,492,391.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 4Open filing 0001213900-26-053991 Dispute this row
Soleus Capital, LLC Ordinary Shares, no par value per share9.110,492,391.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 4Open filing 0001213900-26-053991 Dispute this row
Soleus Capital Group, LLC Ordinary Shares, no par value per share9.110,492,391.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 4Open filing 0001213900-26-053991 Dispute this row
Soleus Capital Management, L.P. Ordinary Shares, no par value per share9.110,492,391.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 4Open filing 0001213900-26-053991 Dispute this row
Soleus GP, LLC Ordinary Shares, no par value per share9.110,492,391.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 4Open filing 0001213900-26-053991 Dispute this row
Guy Levy Ordinary Shares, no par value per share9.110,492,391.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 4Open filing 0001213900-26-053991 Dispute this row
Vanguard Portfolio Management Common Stock5.576,339,99403/31/2026 Filed 2026-04-28SCHEDULE 13GOpen filing 0002100121-26-000048 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 8Open filing 0000102909-26-000428 Dispute this row
Soleus Capital Master Fund, L.P. Ordinary Shares, no par value per share7.68,530,665.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0001213900-26-015652 Dispute this row
Soleus Capital, LLC Ordinary Shares, no par value per share7.68,530,665.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0001213900-26-015652 Dispute this row
Soleus Capital Group, LLC Ordinary Shares, no par value per share7.68,530,665.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0001213900-26-015652 Dispute this row
Soleus Capital Management, L.P. Ordinary Shares, no par value per share7.68,530,665.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0001213900-26-015652 Dispute this row
Soleus GP, LLC Ordinary Shares, no par value per share7.68,530,665.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0001213900-26-015652 Dispute this row
Guy Levy Ordinary Shares, no par value per share7.68,530,665.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 3Open filing 0001213900-26-015652 Dispute this row
Capital World Investors Common Stock1.82,000,000.0009/30/2025 Filed 2025-11-13SCHEDULE 13G/AAmendment 1Open filing 0001422849-25-000073 Dispute this row
Soleus Capital Master Fund, L.P. Ordinary Shares, no par value per share8.69,644,872.0009/30/2025 Filed 2025-11-07SCHEDULE 13G/AAmendment 2Open filing 0001213900-25-107604 Dispute this row
Soleus Capital, LLC Ordinary Shares, no par value per share8.69,644,872.0009/30/2025 Filed 2025-11-07SCHEDULE 13G/AAmendment 2Open filing 0001213900-25-107604 Dispute this row
Soleus Capital Group, LLC Ordinary Shares, no par value per share8.69,644,872.0009/30/2025 Filed 2025-11-07SCHEDULE 13G/AAmendment 2Open filing 0001213900-25-107604 Dispute this row
Soleus Capital Management, L.P. Ordinary Shares, no par value per share8.69,644,872.0009/30/2025 Filed 2025-11-07SCHEDULE 13G/AAmendment 2Open filing 0001213900-25-107604 Dispute this row
Soleus GP, LLC Ordinary Shares, no par value per share8.69,644,872.0009/30/2025 Filed 2025-11-07SCHEDULE 13G/AAmendment 2Open filing 0001213900-25-107604 Dispute this row
Guy Levy Ordinary Shares, no par value per share8.69,644,872.0009/30/2025 Filed 2025-11-07SCHEDULE 13G/AAmendment 2Open filing 0001213900-25-107604 Dispute this row
Capital World Investors Common Stock5.76,382,848.0006/30/2025 Filed 2025-08-13SCHEDULE 13GOpen filing 0001422849-25-000038 Dispute this row
Soleus Capital Master Fund, L.P. Ordinary Shares, no par value per share6.26,904,302.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072155 Dispute this row
Soleus Capital, LLC Ordinary Shares, no par value per share6.26,904,302.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072155 Dispute this row
Soleus Capital Group, LLC Ordinary Shares, no par value per share6.26,904,302.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072155 Dispute this row
Soleus Capital Management, L.P. Ordinary Shares, no par value per share6.26,904,302.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072155 Dispute this row
Soleus GP, LLC Ordinary Shares, no par value per share6.26,904,302.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072155 Dispute this row
Guy Levy Ordinary Shares, no par value per share6.26,904,302.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072155 Dispute this row
Capital International Investors Common Stock0.00.0006/30/2025 Filed 2025-07-07SCHEDULE 13G/AAmendment 5Open filing 0001562230-25-000087 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,024,280 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024117,969
2025235,520
2026254,026

Filings made before the SEC required XML are listed, not extracted.

Back to NovoCure Limited